Rhabdomyosarcomas utilize developmental, myogenic growth factors for disease advantage: A report from the children's oncology group

Pediatric Blood and Cancer

Volumn 46, Issue 3, 2006, Pages 329-338

  Blandford, Mary C ^a   Barr, Frederic G ^b   Lynch, James C ^c   Randall, R L ^a   Qualman, Stephen J ^d   Keller, Charles ^a,e  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^d NATIONWIDE CHILDREN S HOSPITAL   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

Insulin like growth factor; Metastasis; Myogenesis; Platelet derived growth factor; Progression; Rhabdomyosarcoma

Indexed keywords

COMPLEMENTARY DNA; IMATINIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE INHIBITOR; RNA; SOMATOMEDIN B; SOMATOMEDIN C;

ADOLESCENT; ADULT; ARTICLE; CHILD; CHILDHOOD CANCER; DRUG TARGETING; FEMALE; GENE EXPRESSION REGULATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUSCLE DEVELOPMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AUTOCRINE COMMUNICATION; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INFANT; MALE; NEOPLASM PROTEINS; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHABDOMYOSARCOMA; RNA, MESSENGER; SOMATOMEDINS; TRANSCRIPTION, GENETIC;

EID: 32044469857     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20466     Document Type: Article

References (47)

1. Qualman SJ, Coffin CM, Newton WA, et al. Intergroup rhabdomyosarcoma study: Update for pathologists. Pediatr Dev Pathol 1998;1:550-561.
2. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341:342-352.
3. Wexler LH, Helman LJ. Rhabdomyosarcoma and the undifferentiated sarcomas. Philadelphia: Lippincott-Raven; 1997. pp 799-829.
4. Tsokos M, Webber B, Parham D, et al. Rhabdomyosarcoma. A new classification scheme related to prognosis. Arch Pathol Lab Med 1992;116:847-855.
5. Crist W, Gehan E, Ragab A, et al. The third intergroup rhabdomyosarcoma study. J Clin Oncol 1995;13:610-630.
6. Breitfeld PP, Lyden E, Raney RB, et al. Ifosfamide and etoposide are superior to vincristine and melphalan for pediatric metastatic rhabdomyosarcoma when administered with irradiation and combination chemotherapy: A report from the Intergroup Rhabdomyosarcoma Study Group. J Pediatr Hematol Oncol 2001;23:225-233.
7. Wexler LH, Garvin JH, Jr. Pediatric nonrhabdomyosarcoma soft tissue sarcomas: Progress on clinical and biologic fronts [editorial; comment]. J Pediatr 1997;131:508-509.
8. Newton WA, Jr, Gehan EA, Webber BL, et al. Classification of rhabdomyosarcomas and related sarcomas. Pathologic aspects and proposal for a new classification-An intergroup rhabdomyosarcoma study. Cancer 1995;76:1073-1085.
9. Sorensen PH, Lynch JC, Qualman SJ, et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: A report from the children's oncology group. J Clin Oncol 2002;20:2672-2679.
10. Meijerink J, Mandigers C, van de Locht L, et al. A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR. J Mol Diagn 2001;3:55-61.
11. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: Results for patients with nonmetastatic disease. J Clin Oncol 2001;19:3091-3102.
12. Ridgeway AG, Skerjanc IS. Pax3 is essential for skeletal myogenesis and the expression of Six1 and Eya2. J Biol Chem 2001;276:19033-19039.
13. Buckingham M. Skeletal muscle formation in vertebrates. Curr Opin Genet Dev 2001;11:440-448.
14. King JA, Marker PC, Seung KJ, et al. BMP5 and the molecular, skeletal, and soft-tissue alterations in short ear mice. Dev Biol 1994;166:112-122.
15. Driman D, Thorner PS, Greenberg ML, et al. MYCN gene amplification in rhabdomyosarcoma. Cancer 1994;73:2231-2237.
16. Bayani J, Thorner P, Zielenska M, et al. Application of a simplified comparative genomic hybridization technique to screen for gene amplification in pediatric solid tumors. Pediatr Pathol Lab Med 1995;15:831-844.
17. Hachitanda Y, Toyoshima S, Akazawa K, et al. N-myc gene amplification in rhabdomyosarcoma detected by fluorescence in situ hybridization: Its correlation with histologic features. Mod Pathol 1998;11:1222-1227.
18. Felix CA, Kappel CC, Mitsudomi T, et al. Frequency and diversity of p53 mutations in childhood rhabdomyosarcoma. Cancer Res 1992;52:2243-2247.
19. Mark HF, Brown S, Sun CL, et al. Fluorescent in situ hybridization detection of HER-2/neu gene amplification in rhabdomyosarcoma. Pathobiology 1998;66:59-63.
20. Meddeb M, Valent A, Danglot G, et al. MDM2 amplification in a primary alveolar rhabdomyosarcoma displaying a t(2;13)(q35;q14). Cytogenet Cell Genet 1996;73:325-330.
21. Khatib ZA, Matsushime H, Valentine M, et al. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res 1993;53:5535-5541.
22. Epstein JA, Shapiro DN, Cheng J, et al. Pax3 modulates expression of the c-Met receptor during limb muscle development. Proc Natl Acad Sci USA 1996;93:4213-4218.
23. Hahn H, Wojnowski L, Zimmer AM, et al. Rhabdomyosarcomas and radiation sensitivity in a mouse model of Gorlin syndrome. Nat Med 1998;4:619-622.
24. Gorlin RJ. Nevoid basal-cell carcinoma syndrome. Medicine 1987;66:98-113.
25. Borycki A, Brown AM, Emerson CP, Jr. Shh and Wnt signaling pathways converge to control Gli gene activation in avian somites. Development 2000;127:2075-2087.
26. Amthor H, Christ B, Weil M, et al. The importance of timing differentiation during limb muscle development. Curr Biol 1998;8:642-652.
27. Zuniga A, Quillet R, Perrin-Schmitt F, et al. Mouse twist is required for fibroblast growth factor-mediated epithelial-mesenchymal signalling and cell survival during limb morphogenesis. Mech Dev 2002;114:51.
28. Sharp R, Recio JA, Jhappan C, et al. Synergism between INK4a/ARF inactivation and aberrant HGF/SF signaling in rhabdomyosarcomagenesis. Nat Med 2002;8:1276-1280.
29. Buckingham M, Bajard L, Chang T, et al. The formation of skeletal muscle: From somite to limb. J Anat 2003;202:59-68.
30. Barr FG, Chatten J, D'Cruz CM, et al. Molecular assays for chromosomal translocations in the diagnosis of pediatric soft tissue sarcomas. JAMA 1995;273:553-557.
31. Keller C, Arenkiel BR, Coffin CM, et al. Alveolar rhabdomyosarcomas in conditional Pax3:Fkhr mice: Cooperativity of Ink4a/ARF and Trp53 loss of function. Genes Dev 2004;18:2614-2626.
32. Anderson MJ, Shelton GD, Cavenee WK, et al. Embryonic expression of the tumor-associated PAX3-FKHR fusion protein interferes with the developmental functions of Pax3. Proc Natl Acad Sci USA 2001;98:1589-1594.
33. Hahn H, Wojnowski L, Specht K, et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J Biol Chem 2000;275:28341-28344.
34. Crosby JR, Seifert RA, Soriano P, et al. Chimaeric analysis reveals role of Pdgf receptors in all muscle lineages. Nat Genet 1998;18:385-388.
35. Soriano P. The PDGF alpha receptor is required for neural crest cell development and for normal patterning of the somites. Development 1997;124:2691-2700.
36. Fernandez AM, Dupont J, Farrar RP, et al. Muscle-specific inactivation of the IGF-I receptor induces compensatory hyperplasia in skeletal muscle. J Clin Invest 2002;109:347-355.
37. Prelle K, Wobus AM, Krebs O, et al. Overexpression of insulin-like growth factor-II in mouse embryonic stem cells promotes myogenic differentiation. Biochem Biophys Res Commun 2000;277:631-638.
38. Pirskanen A, Kiefer JC, Hauschka SD. IGFs, insulin, Shh, bFGF, and TGF-beta1 interact synergistically to promote somite myogenesis in vitro. Dev Biol 2000;224:189-203.
39. Germain-Lee EL, Janicot M, Lammers R, et al. Expression of a type 1 insulin-like growth factor receptor with low affinity for insulin-like growth factor II. Biochem J 1992;281:413-417.
40. Irusta PM, DiMaio D. A single amino acid substitution in a WW-like domain of diverse members of the PDGF receptor subfamily of tyrosine kinases causes constitutive receptor activation. EMBO J 1998;17:6912-6923.
41. Lau MM, Stewart CE, Liu Z, et al. Loss of the imprinted 1GF2/cation-independent mannose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev 1994;8:2953-2963.
42. LeRoith D, Roberts CT, Jr. The insulin-like growth factor system and cancer. Cancer Lett 2003;195:127-137.
43. Rubin BP, Schuetze SM, Eary JF, et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002;20:3586-3591.
44. Cohen MH, Moses ML, Pazdur R. Gleevec(TM) for the treatment of chronic myelogenous leukemia: U.S. Food and Drug Administration Regulatory Mechanisms, Accelerated Approval, and Orphan Drug Status. Oncologist 2002;7:390-392.
45. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-230.
46. Keller C, Hansen MS, Coffin CM, et al. Pax3:Fkhr interferes with embryonic Pax3 and Pax7 function: Implications for alveolar rhabdomyosarcoma cell of origin. Genes Dev 2004;18:2608-2613.
47. Schofield D, Triche TJ. cDNA microarray analysis of global gene expression in sarcomas. Curr Opin Oncol 2002;14:406-411.